A growing number of companies seek to unleash these unusual T cells against cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Signal Transduction and Targeted Therapy Open Access 22 November 2023
-
Cancer immunotherapy with γδ T cells: many paths ahead of us
Cellular & Molecular Immunology Open Access 22 July 2020
-
More bricks in the wall against SARS-CoV-2 infection: involvement of γ9δ2 T cells
Cellular & Molecular Immunology Open Access 28 May 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
21 April 2020
A Correction to this paper has been published: https://doi.org/10.1038/s41587-020-0526-z
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. γδ T cells bring unconventional cancer-targeting to the clinic — again. Nat Biotechnol 38, 389–391 (2020). https://doi.org/10.1038/s41587-020-0487-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0487-2
This article is cited by
-
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Signal Transduction and Targeted Therapy (2023)
-
Cancer immunotherapy with γδ T cells: many paths ahead of us
Cellular & Molecular Immunology (2020)
-
More bricks in the wall against SARS-CoV-2 infection: involvement of γ9δ2 T cells
Cellular & Molecular Immunology (2020)